140 likes | 263 Views
Progress of Artemisinin production in East Africa. Advanced Bio- Extracts Limited Lisa Amenya. Perspective - who we are. Advanced Bio- Extracts Limited (ABE) Private company with four production subsidiaries operating in the East Africa region African Artemisia Limited (Tanzania)
E N D
Progress of Artemisinin production in East Africa Advanced Bio- Extracts Limited Lisa Amenya
Perspective - who we are... • Advanced Bio- Extracts Limited (ABE) • Private company with four production subsidiaries operating in the East Africa region • African Artemisia Limited (Tanzania) • East African Botanicals Limited (Kenya) • East African Botanicals U Limited (Uganda) • Botanical Extracts EPZ Limited (Kenya)
Objectives • To create a predictable, affordable supply of artemisinin and derivatives – feeding into the ACT chain. • To inject a significant supply of artemisinin to solve industry shortfalls within a 2- year period. • To contribute significantly to bringing the whole chain of ACT production to Africa, in a sustainable way.
Progress on production of artemisinin in East Africa • Can production in East Africa be competitive? Under the right conditions – YES • Raw material • Stable supply being built up rapidly. • Using a range of farming patterns in East Africa. • Processing • Producing and selling small commercial quantities of artemisinin. • Will be supplying more significant commercial quantities of artemisinin by year end 2006. • About to commission a major artemisinin processing and extraction plant in Kenya. • Production of artemisinin based derivatives from the Kenya plant by mid- 2007.
What we are offering… • Supply of artemisinin and derivatives at predictable volumes and prices. • To work with other extractors to purify and derivative their products. • Long- term relationships with growers.
Challenges • Market certainty – clarification of synthetics. • Much more complicated than it appears. • Economy of scale required. • To overcome technical challenges for cost effectiveness • Too much fragmentation will not enhance viability. • Focus on comparative advantages of the region. • Financial support for technical development and investment.